Xeris Biopharma Holdings (XERS) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- —
- Estimate
- —
- Surprise
- -154.1%
- Revenue (period 2026-06-30)
- $92.1M
- Score at report (before → after)
- 6.4 → 6.4/10
Revenue source: xbrl.
How the report landed
TrendMatrix's engine moved from Hold (6.4/10) to Sell at 6.4/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates XERS Buy (Wait) at 6.2/10.
0 of the last 4 quarters beat the estimate; this quarter's -154.1% surprise compares with a +343.0% four-quarter average. Next scheduled report: 2026-11-05.
What supports the rating
- Positive news sentiment (+0.67)
- Strong growth profile
What argues against it
- Concentration risk — Supplier: Regis Technologies
- Concentration risk — Supplier: Lonza Tampa
- News modifier +1: HOLD_IF_HOLDING → STRONG_BUY_WAIT
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $8.70
- Entry target
- $8.22
- Price target
- $10.19
- Stop
- $7.39
- Upside to target
- +17.1%
- Reward-to-risk
- 1.1:1
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
XERS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $1.59B
- P/E (fwd)
- 22.3
- 52-week range
- $5.25–$10.08
- Off 52-week high
- 13.7%
- RSI (14)
- 59
- Volume vs avg
- 0.90×
- Score today
- 6.2/10